Get started
Author

Jonas Ristau

EML4‐ALK fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK + non‐small cell lung cancer
2018 · Petros Christopoulos, Volker Endris, et al. · International Journal of Cancer · 138
PDF
Identification of a highly lethal V3 + TP53 + subset in ALK + lung adenocarcinoma
2018 · P. Christopoulos, M. Kirchner, et al. · International Journal of Cancer · 93
PDF
FAP imaging in rare cancer entities—first clinical experience in a broad spectrum of malignancies
2021 · K. Dendl, R. Finck, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 64
PDF
Impact of Primary Staging with Fibroblast Activation Protein Specific Enzyme Inhibitor (FAPI)-PET/CT on Radio-Oncologic Treatment Planning of Patients with Esophageal Cancer
2020 · J. Ristau, F. L. Giesel, et al. · Molecular Imaging and Biology · 45
PDF
Impact of FAPI-PET/CT on Target Volume Definition in Radiation Therapy of Locally Recurrent Pancreatic Cancer
2021 · Jakob Liermann, Mustafa Syed, et al. · Cancers · 44
PDF
Adaptive MR-Guided Stereotactic Radiotherapy is Beneficial for Ablative Treatment of Lung Tumors in High-Risk Locations
2022 · Sebastian Regnery, Carolin Buchele, et al. · Frontiers in Oncology · 39
MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial
2022 · P. Hoegen, K. S. Zhang, et al. · Radiation Oncology · 29
PDF
Magnetic resonance guided adaptive stereotactic body radiotherapy for lung tumors in ultracentral location: the MAGELLAN trial (ARO 2021-3)
2022 · Sebastian Regnery, Jonas Ristau, et al. · Radiation Oncology · 28
PDF
Suitability of Circulating miRNAs as Potential Prognostic Markers in Colorectal Cancer
2014 · Jonas Ristau, Jürgen Staffa, et al. · Cancer Epidemiology Biomarkers & Prevention · 28
SMART ablation of lymphatic oligometastases in the pelvis and abdomen: Clinical and dosimetry outcomes
2022 · Sebastian Regnery, Carolin Buchele, et al. · Radiotherapy and Oncology · 27
Dosimetric Benefit of Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy of Liver Metastases
2022 · Fabian Weykamp, Efthimios Katsigiannopulos, et al. · Cancers · 25
PDF
Stereotactic Radiosurgery With Concurrent Immunotherapy in Melanoma Brain Metastases Is Feasible and Effective
2020 · Jakob Liermann, Julia K. Winkler, et al. · Frontiers in Oncology · 23
PDF
Stereotactic MRI-guided radiation therapy for localized prostate cancer (SMILE): a prospective, multicentric phase-II-trial
2022 · J. Ristau, J. Hörner-Rieber, et al. · Radiation Oncology · 19
PDF
Stereotactic magnetic resonance-guided online adaptive radiotherapy of adrenal metastases combines high ablative doses with optimized sparing of organs at risk
2022 · Philipp Hoegen, Efthimios Katsigiannopulos, et al. · Clinical and Translational Radiation Oncology · 17
PDF
Predicting the Risk of Metastases by PSMA-PET/CT—Evaluation of 335 Men with Treatment-Naïve Prostate Carcinoma
2021 · Stefan A. Koerber, Johannes Boesch, et al. · Cancers · 17
PDF
Simultaneous integrated boost concepts in definitive radiation therapy for esophageal cancer: outcomes and toxicity
2021 · J. Ristau, M. Thiel, et al. · Radiation Oncology · 17
PDF
Dosimetric benefit of online treatment plan adaptation in stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer
2024 · Christoph A. Fink, Carolin Buchele, et al. · Frontiers in Oncology · 12
PDF
A fully automated machine-learning-based workflow for radiation treatment planning in prostate cancer
2025 · Jan-Hendrik Bolten, David Neugebauer, et al. · Clinical and Translational Radiation Oncology · 10
PDF
A body mass index-based method for “MR-only” abdominal MR-guided adaptive radiotherapy
2023 · Carolin Rippke, C. Katharina Renkamp, et al. · Zeitschrift für Medizinische Physik · 7
Stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer – Acute toxicity and patient-reported outcomes in the prospective, multicenter SMILE phase II trial
2024 · C.A. Fink, J. Ristau, et al. · Clinical and Translational Radiation Oncology · 5
PDF
Detecting and Locating the Site of Local Relapse Using 18F-PSMA-1007 Imaging After Primary Treatment of 135 Prostate Cancer Patients—Potential Impact on PSMA-Guided Radiation Therapy
2022 · S. A. Koerber, R. C. Kroener, et al. · Molecular Imaging and Biology · 5
PDF
MR-linac based radiation therapy in gastrointestinal cancers: a narrative review
2024 · Jonas Ristau, Juliane Hörner-Rieber, et al. · Journal of Gastrointestinal Oncology · 4
Korrelation von PSMA-Uptake und Metastasierungswahrscheinlichkeit bei Prostatakarzinom nach PSMA-PET/CT mit 18-F und 68-Ga
2023 · J. Boesch, S. A. Koerber, et al. · Nuklearmedizin - NuclearMedicine
SMILE: Stereotaktische MRT-geführte Radiotherapie von lokal begrenzten Prostatakarzinomen
2022 · J. Ristau, J. Hörner-Rieber, et al. · Forum
PD-0408 Long-term outcome after definitive photon vs. combined proton/photon irradiation for prostate cancer
2022 · S.A. Koerber, K. Ebel, et al. · Radiotherapy and Oncology
Works count: 34
Citation count: 696
H-index: 16
I10-index: 18
Year
Topic
Type